Weiss Ratings Reaffirms Sell (D-) Rating for Nautilus Biotechnology (NASDAQ:NAUT)

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Nautilus Biotechnology (NASDAQ: NAUT) in a recent research report.
• Nautilus Biotechnology's stock opened at $0.90, with a market capitalization of approximately $114 million, despite having reported an earnings per share of ($0.12) for the last quarter.
• Insider trading activity shows CEO Sujal M. Patel purchased 116,500 shares at $0.67 per share, representing a 1.15% increase in his position, amidst growing insider ownership at 41.10% of the company.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Nautilus Biotechnology Stock Performance

Shares of NAUT opened at $0.90 on Wednesday. Nautilus Biotechnology has a fifty-two week low of $0.62 and a fifty-two week high of $3.03. The company has a market capitalization of $113.96 million, a price-to-earnings ratio of -1.74 and a beta of 1.48. The firm has a 50-day simple moving average of $0.74 and a 200-day simple moving average of $0.76.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. Equities research analysts forecast that Nautilus Biotechnology will post -0.57 EPS for the current year.

Insider Buying and Selling at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 116,500 shares of the company's stock in a transaction dated Friday, September 5th. The stock was acquired at an average cost of $0.67 per share, with a total value of $78,055.00. Following the purchase, the chief executive officer directly owned 10,258,221 shares in the company, valued at approximately $6,873,008.07. This trade represents a 1.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have purchased 220,000 shares of company stock worth $147,635. Company insiders own 41.10% of the company's stock.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in Nautilus Biotechnology in the 1st quarter worth $31,000. Millennium Management LLC bought a new stake in shares of Nautilus Biotechnology during the 4th quarter valued at about $63,000. Sentinel Trust Co. LBA boosted its stake in Nautilus Biotechnology by 9.8% during the 1st quarter. Sentinel Trust Co. LBA now owns 280,000 shares of the company's stock valued at $241,000 after purchasing an additional 25,000 shares during the period. Clarius Group LLC boosted its stake in Nautilus Biotechnology by 36.1% during the 1st quarter. Clarius Group LLC now owns 866,586 shares of the company's stock valued at $746,000 after purchasing an additional 230,054 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Nautilus Biotechnology in the 1st quarter worth approximately $167,000. Institutional investors and hedge funds own 50.71% of the company's stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.